MedWatch

Senior physician: Biomarkers are the future

Amgen discovered a new and highly significant biomarker recently. The U.S. company hopes that it can help advance personalized medicine for colon cancer patients.

A retrospective analysis of the biomarker RAS has shown clear signs of improved survival for colon cancer patients – the third most common cancer disease in Denmark.

The analysis showed improved overall survival over six months for patients with WAS wild type, who were treated with a combination of Amgen’s Vectibix and Folfox, compared with those treated only with Folfox. The positive results were presented at the yearly meeting of the American Society of Clinical Oncology in Chicago last week.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier